Abstract 1498P
Background
A pilot study has revealed a significant correlation between high levels of circulating HGF and poor response to ICIs therapy in late-stage NSCLC patients treated with ICIs. This study aimed to evaluate the prognostic value and role of the HGF/MET pathway in first-line immunotherapy treatment in advanced NSCLC patients.
Methods
We included 82 consecutive patients, 49 treated with immunotherapy and 33 treated with chemotherapy alone as a group control. We analysed the plasma levels of HGF by ELISA. Immunohistochemistry was used to assess the expression levels of PD-L1, MET, and CD8+ T-Cell infiltration. The contribution of HGF/MET to NSCLC response to ICIs was further investigated by culturing peripheral blood mononuclear cells (PBMC)stimulated with 10 μg/mL phytohemagglutinin (PHA) and/or pembrolizumab (20 nM). The cells were cultured with recombinant HGF or co-cultured with NSCLC patients-derived explants.in the presence of cMET inhibitors Crizotinib or SGX. The immune response was quantified through CD8+ activation and INFγ production.
Results
Correlation tests demonstrated that lower HGF levels were associated with a good response to ICIs (RR=2.143; p=0.004) and low progression (RR=0; p=0.01). Patients with low HGF levels (< Q1) at treatment initiation had longer progression-free survival (PFS) (841 vs 136.5 days; HR = 0.26 95% CI 0.1292-0.5411; p=0.0003) and longer overall survival (OS) (median not reached vs. 489 days; HR 0.36; 95% CI 0.1505-0.8408; p=0.02). Furthermore, when activated PBMCs were cultured in the presence of recombinant HGF or on NSCLC monolayer, the activation/proliferation of CD3+CD8+ lymphocytes, was inhibited, even in the presence of pembrolizumab. The addition of HGF/MET inhibitors (Crizotinib and SGX) suppressed the immunosuppressive properties of recombinant HGF or NSCLC, stimulating INFγ production.
Conclusions
Our study found that high levels of HGF in the peripheral blood are associated with poor response to ICIs, disease progression, and shorter survival in patients with advanced NSCLC. Furthermore, we showed through in vitro experiments that inhibiting the HGF/MET signaling pathway could be a promising therapeutic approach to enhance the efficacy of ICIs in this patient population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Paris Saclay, UVSQ.
Funding
Legs Poix Subvention (2018).
Disclosure
E. Giroux-Leprieur: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Advisory Board: AstraZeneca, Ipsen, Janssen, Lilly, MSD, Novartis, Pfizer, Sanofi, Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
1509TiP - The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor
Presenter: Laura Mezquita
Session: Poster session 21
1510TiP - Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant non-small cell lung cancer (NSCLC) according to TP53 mutational status (TEMPLE-2/NCT05785208)
Presenter: Antonio Vitale
Session: Poster session 21
1515P - Maintenance rucaparib after first-line platinum-based chemotherapy in advanced esophagogastric (OG) adenocarcinoma: Interim results from the PLATFORM trial
Presenter: Anderley Gordon
Session: Poster session 21
1518P - Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study
Presenter: Keun-Wook Lee
Session: Poster session 21
1520P - Perioperative treatment in resectable gastric cancer with spartalizumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): The GASPAR phase II trial
Presenter: Melanie Dos Santos
Session: Poster session 21
1521P - Addition of durvalumab to CROSS in oesophageal adenocarcinoma is feasible and safe
Presenter: Hans Schloesser
Session: Poster session 21